Critical Survey: Celator Pharmaceuticals (CPXX) vs. Incyte (INCY)
Celator Pharmaceuticals (NASDAQ: CPXX) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.
Institutional & Insider Ownership
90.7% of Incyte shares are held by institutional investors. 17.7% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and target prices for Celator Pharmaceuticals and Incyte, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Incyte has a consensus price target of $142.86, indicating a potential upside of 53.51%. Given Incyte’s higher possible upside, analysts plainly believe Incyte is more favorable than Celator Pharmaceuticals.
Valuation and Earnings
This table compares Celator Pharmaceuticals and Incyte’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Incyte||$1.11 billion||17.76||$104.22 million||($0.80)||-116.33|
Incyte has higher revenue and earnings than Celator Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Celator Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Celator Pharmaceuticals and Incyte’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Incyte beats Celator Pharmaceuticals on 7 of the 10 factors compared between the two stocks.
Celator Pharmaceuticals Company Profile
Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company’s product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
Receive News & Ratings for Celator Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celator Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.